Organic Active Ingredients TRIZ Cases

Continuous distillation concentrates microbial or marine oils into high-DHA ester fractions while reducing process time, cost, and isomerization.

Indoleacetic acid derivatives improve antitussive and antiasthmatic effects while reducing side effects and safety limits of existing drugs.

A 5'-acetoacetyl uridine ester improves oral uptake and releases both uridine and acetoacetate for cerebral energy failure disorders.

Structural changes in domide molecular glue derivatives improve anti-tumor activity while lowering toxicity, including for low receptor expression tumors.

A succinic acid salt crystal form improves solubility, stability, and handling of complement factor B inhibitors for reproducible drug manufacturing.

Amide-linked orotic acid derivatives improve water and alcohol solubility while preserving melanin inhibition and skin whitening activity.

Modular PROTAC degraders bind MLLT1 and MLLT3 and recruit E3 ligase to overcome weak modulation and enable selective cancer targeting.

An amorphous BMS-986165 dispersion in HPMCAS maintains stability and bioavailability under elevated gastric pH while enabling colon release.

Thermal micropores help a triptan patch cross the stratum corneum, improving migraine drug delivery while reducing skin irritation.

Low-dose tacrolimus activates the BMP-SMAD axis via FKBP12 to prevent muscle atrophy and promote hypertrophy without immunosuppression.

Deuterium-tuned Helios degraders improve IKZF2 selectivity and metabolic stability while reducing Treg immunosuppressive activity.

Substituted heterocyclic compounds inhibit Tyk2 signaling while lowering efflux ratios, improving IL-12, IL-23, and IFNα pathway modulation.

Specific Lactobacillus mucosae strains with soluble dietary fiber modulate the gut microbiome to reduce metabolic syndrome markers.

Combining antibiotics with an aryladamantane compound helps counter cancer resistance while improving cytotoxicity, apoptosis, and IL-6 reduction.

Stabilized mRNA in lipid nanoparticles enables sustained therapeutic protein production without genomic integration risks.

Small molecules that modulate PTPN2 boost lymphoid cell activity, offering a lower-cost alternative to complex CAR-T manufacturing.

Protein lysine methyltransferase inhibitors based on quinoxaline-2,3-diamines target juvenile schistosomes, resistant liver flukes, and MRSA.

Immediate IV cangrelor bridges the post-surgery gap before aspirin, helping prevent acute shunt thrombosis in neonates and other pediatric patients.

An amide and alkyl lactate solvent system keeps high-content abamectin concentrates stable in cold storage and prevents crystallization after dilution.

Isookanin suppresses JAK1, TLR-2, COX-2, and kallikrein-5 to treat inflammation while avoiding skin irritation and cytotoxicity.

F(ab')2-based humanized 4-1BB antibodies preserve T cell activation and anti-tumor effects while reducing hepatotoxicity and thrombocytopenia.

A microfabricated cardiac anisotropic sheet enables human cardiomyocyte assays to detect conduction changes and reentrant arrhythmias.

Dry powder epinephrine with controlled particle size improves nasal deposition and absorption while remaining simple for layperson emergency use.

Multiple nitric oxide donor groups on dendrimers or silica improve release control, stability, and tissue-targeted delivery.

Small-molecule CFTR activators increase tear secretion and normalize stool output to treat dry eye and constipation more effectively.

Systemic lotilaner dosing eradicates ticks attached to humans, helping prevent Lyme and other vector-borne disease transmission.

Ni-NTA lipidoid nanoparticles bind His-tagged proteins via nickel coordination, enabling less invasive intracellular delivery and stronger genome editing activity.

A continuous burst-release coat around centanafadine particulates balances fast onset with prolonged and enteric release in high-dose bead formulations.

Ligand-guided constructs use receptor-mediated uptake and membrane penetration to deliver toxic payloads into resistant tumor cells.

Directing pooled human IgG to the olfactory epithelium bypasses the blood-brain barrier, lowering dose and systemic exposure in CNS treatment.

Removing magnesium stearate and using filgotinib maleate Form I with fumaric acid improves formulation stability and bioavailability.

Targeting P2X4 with a benzene-ring scaffold improves antagonistic activity, selectivity, metabolic stability, and toxicity profile for cough therapy.

A dCas9-VP64 and guide RNA approach activates LAMA1 in muscle to compensate for laminin α2 deficiency in MDC1A.

Enzyme-labile protecting groups enable physiological cross-linking of nanostructures, improving bioconjugation stability for delivery and detection.

Oral WX-671 inhibits TMPRSS2 to block coronavirus entry into host cells, lowering viral load while limiting cytotoxicity.

Balanced water and cosolvent levels plus actuator geometry keep ipratropium bromide stable and doses consistent in an MDI.

Androstane derivatives selectively activate SERCA2a with limited Na+/K+ ATPase inhibition, supporting oral heart failure treatment with lower arrhythmogenic risk.

Small-molecule AAT modulators restore protease regulation and reduce hepatic aggregation to address both lung and liver AATD.

Using phospholipid ether carriers, these conjugates improve tumor-selective uptake and cytotoxicity while limiting off-target toxicity in healthy cells.

An oral HPC regimen uses sustained dosing from 14 weeks to maintain therapeutic levels and improve preterm birth prevention versus injections.

A stepwise route combines coupling, bromination, and hydrogenation to scale P2X3 antagonist synthesis for clinically useful quantities.

Small-molecule STING inhibitors curb excessive signaling to treat cancer-linked inflammation and autoinflammatory disorders.

Targeting the IL-4 receptor helps treat resistant atopic dermatitis while reducing biomarkers, pruritus, and dependence on topical corticosteroids.

A 3D triazole-linked polymer conjugate enables sustained ocular drug release, then biodegrades for rapid clearance after treatment.

Sub-anesthetic ketamine alone or with NAP raises ADNP expression while limiting neurotoxicity in ADNP syndrome and related conditions.

Biomarker-guided TGF-β2 suppression paired with irinotecan improves anti-tumor response while helping avoid drug and cross-resistance.

Dual EGFR and B7-H3 binding helps address resistance and multi-pathway limits while boosting ADCC and antibody stability.

Adding at least 5% carbohydrate to an L-tryptophan or L-tyrosine oral liquid promotes insulin response and improves brain uptake.

Site-specific PEGylation at a defined FGF-21 residue creates a homogeneous liquid formulation with longer half-life and 12-month stability.

Cannflavins A, B, and C inhibit Trk signaling to reduce cancer cell viability and invasion while limiting cytotoxicity to healthy cells.

c-Met expression testing guides telisotuzumab vedotin treatment for NSCLC, targeting tumor cells and limiting adverse events in non-responders.

Cell-membrane coating improves blood compatibility while ultrasound-generated acoustic pores drive nucleic acids into cells.

Modified CHO-M cells produce full-length, heavily glycosylated lubricin at yields above 2.0 g/L for joint and dry-eye lubrication.

Creatine supports ATP recycling and brain-area enrichment to address mental fatigue, reduced motivation, and concentration difficulties in PVFS.

Controlled oral release delivers 50%–98% of daily minoxidil within 12 hours to sustain therapy and limit adverse effects.

A rotary tablet press and tailored excipient matrix produce soft-chew tablets with controlled hardness, friability, weight, and texture.

An intravenous sulcardine profile targets rapid atrial fibrillation cardioversion while limiting prolonged exposure and proarrhythmic risk.

Multiple complementary domains let oligonucleotides use endogenous ADAR for adenosine editing without disrupting functional elements.

Off-target immune reactions can limit T-cell activation; targeted antibody conjugates deliver Cbl-b inhibitors to effector T cells.

Ubiquitin ligase recruitment tags Btk for proteasomal degradation, addressing inadequate inhibition and reducing BtkC481S in CLL cells.

Existing options for BRG1- and BRM-altered disorders are inadequate; Formula I pyrazine derivatives modulate the BAF complex.

ArkI phosphorylates tRNA uridine at the 2′ hydroxyl group to improve thermal and RNase resistance, while KptA enables reversible removal.

Nanoparticles pair intracellular DNA delivery with a type 1 interferon receptor pathway inhibitor to increase transgene expression and reduce cytokines.

A ferulic acid metabolite, 3-HMPPA provides sympathetic nerve activation for food and drink compositions while addressing safety uncertainty.

Controlled-humidity manufacturing helps prevent lisdexamfetamine deliquescence while supporting a palatable, rapidly dissolving orodispersible tablet.

Guanosine-rich sequences form a G-quadruplex to improve oligonucleotide stability and permeability against resistant blood cancer cells.

Replacing limited theaflavin compositions, this compound promotes myoblast proliferation and helps inhibit muscle atrophy in food and pharmaceutical products.

Lipase- and pH-responsive layers protect medicaments in the stomach and trigger controlled release in the duodenum.

A 12- to 14-day teplizumab course paired with a DYRK1A inhibitor combines immune tolerance with beta-cell regeneration for Type 1 diabetes.

Systemic MEK inhibitors can cause serious side effects; these topical gels target skin lesions while minimizing dermal irritation.

Liposome and niosome formulations protect miR-29 antagonists from degradation and improve transdermal delivery for collagen production in skin.

NTCP-targeting benzothiadiazepine compounds block HBV and HDV entry into liver cells, addressing limited viral-entry treatment options.

Current FLT3 inhibitors may leave bone marrow blasts largely unaffected; crenolanib targets FLT3-mutant AML with additional abnormalities.

Two-stage shear and high-pressure jet pulverization produces 1–10 μm aripiprazole suspensions while reducing contamination in aseptic processing.

Chemically modified chondroitin sulfate polymers release nitric oxide to reduce bacterial burden and accelerate closure in infected chronic wounds.

Low-dose oral-mucosal dexmedetomidine treats agitation in dementia while limiting sedation and cardiovascular side effects.

Balanced crystalloid establishes an ammonium sulfate gradient to improve drug encapsulation while preserving extracellular vesicle integrity and activity.

Layered bioresorbable stent polymers provide temporary structural strength while releasing therapeutic substance gradually as each layer erodes.

Alternating intranasal metoclopramide treatment and drug-free intervals target gastroparesis while reducing tardive dyskinesia and adverse reactions.

Sequence-specific small RNAs bind target mRNA to suppress cancer cell activity, offering a more precise approach than broad conventional treatment.

A peptide linker connects tumor-targeting ligands with camptothecin derivatives to address ADC toxicity and strengthen anti-tumor activity.

Existing antiresorptive therapies can limit bone loss without building sufficient density; these compounds stimulate osteoblasts for bone formation.

Learn how GlyT1 inhibitors reduce ALA, porphobilinogen, and other heme intermediates in hepatic porphyria treatment.

Refractory free-light-chain diseases lack targeted diversity; this Vκ4-1-IgLC sequence supports antibodies that block Integrin-FAK signaling.

An SBEβCD inclusion complex helps solubilize meloxicam, while bicarbonate and rizatriptan support faster, sustained migraine relief.

CD80-binding peptide sequences attach to drug-carrier surfaces to improve cellular uptake and address limited peptide-based delivery options.

LXR agonists and fatty acids raise lipid synthesis and secretion in cultured mammary epithelial cells, supporting milk-component production.

Systemic drug-loaded nanoparticles can diffuse indiscriminately; this MSC-carried PEG-OES fibril approach supports targeted release with fewer systemic side effects.

Dextromethorphan reduces clozapine-induced sialorrhea while limiting memory, constipation, and antipsychotic-effect trade-offs.

Frequent topical application can hinder compliance; this oral formulation uses daily modified release to maintain therapeutic minoxidil levels.

TGF-β inhibition helps prevent fibrosis in corneal endothelial cell culture while preserving ZO-1 and Na+/K+-ATPase functions for transplantation.

By lowering Golgi PtdIns4P, PI4KB inhibitors stabilize ATGL, enhance lipolysis, and reduce hepatic triglyceride levels in NASH.

Dissolved before use, the chlorhexidine-cetylpyridinium solid reduces water, packaging, and preservatives while targeting oral biofilm.

Hydrated ketone saxitoxins can epimerize at C11; non-hydrated 11,13-modified compounds preserve diastereomer stability for selective NaV1.7 pain inhibition.

Acids and organic solvents dissolve rifabutin at high concentration, supporting injectable or inhaled delivery without costly lyophilization.

Direct inhalation delivers EGCG to the lungs for pulmonary fibrosis, helping reduce dose and systemic exposure while broadening the treatment window.

Oligo-γ-glutamic acid lipids replace PEGylated stabilizers in lipid nanoparticles to reduce aggregation and hypersensitivity during mRNA delivery.

Antibody therapies bring stability and manufacturing burdens, while small molecules can lack selectivity; CyTaCs combine CCR2 targeting with recruited immune cytotoxicity.

A heterobifunctional linker joins therapeutic drugs to HSA at sulfhydryl position 34, supporting longer circulation and tumor or inflammation targeting.

PI4KB inhibitor perfusion lowers Golgi PtdIns4P, increases ATGL-driven lipolysis, and reduces triglycerides in steatotic liver grafts ex vivo.

HPLC with charged aerosol detector resolves OXY133 impurities lacking chromophores, achieving 0.01% detection limits without derivatization.

Phenoxymethyl heterocyclic compounds inhibit phosphodiesterase 10 to treat schizophrenia negative symptoms and cognitive impairments.

Delphinidin glycoside neutralizes oxidant stress in lacrimal gland tissue to restore natural secretion and provide sustained dry eye relief.

Conjugating levorphanol to oxoacids or polyethylene glycols creates abuse-resistant prodrugs that require enzymatic breakdown to release the active analgesic.

Acidifying agents lower saliva pH to enhance melatonin solubility, resolving low bioavailability from high oral pH.

Macrocyclic kinase inhibitors resolve selectivity trade-offs by targeting tropomyosin receptor kinases to suppress tumor growth.

Combining semaglutide, firsocostat, and cilofexor treats non-alcoholic steatohepatitis through multi-pathway intervention.

Circulating B cell subset frequency distributions predict kinase inhibitor treatment response in indolent B cell lymphoma patients.

Pre-administering TNF-alpha or IL-6 inhibitors before CD3 bispecific antibodies prevents cytokine release syndrome while maintaining antineoplastic efficacy.

Optimized particle size and protective excipients resolve stability-bioavailability trade-off, achieving 85% dissolution in 15 minutes.

Compound III reduces psychiatric adverse events and relapse rates in schizophrenia patients, stabilizing disease progression.

Aldosterone administration stimulates elastin deposition in scarred vasculature, reducing heart stiffness and improving cardiac function.

Compounds inhibit LINE1 and HERV-K reverse transcriptases to treat cancer, autoimmune disorders, and neurological diseases.

7-substituted indole derivatives inhibit Mcl-1 protein activity through specific structural substitutions.

Tricyclic derivatives inhibit PARP-1 and tankyrase to treat neuropathic pain, neurodegenerative diseases, and cardiovascular conditions.

A 1,3-disubstituted ketene compound activates multiple peroxisome proliferator-activated receptor subtypes to modulate metabolic pathways.

Dasatinib inhibits LCK kinase to boost CD3-targeted gene transfer, resolving the trade-off between transduction efficiency and TCR downregulation.

Reducing cystatin C activity enhances cathepsin B function, addressing ineffective current therapies by lowering amyloid beta accumulation.

Dipping technology applies a semi-permeable coating to a tablet core to customize drug release rates, reducing manufacturing complexity and cost.

Segmenting the formulation into immediate and sustained portions regulates absorption kinetics, preventing rapid clearance while avoiding toxic accumulation.

Bio-adhesive intranasal testosterone gels deliver sustained hormone absorption through optimized nasal cavity deposition.

Fluorine substitutions at the C2, C4, or C6 positions of the ribose ring improve stability and bioavailability to treat mitochondrial diseases.

Substituted quinazoline derivatives inhibit KRAS G12C mutations while preventing drug-resistant adaptations and improving metabolic stability.

Replaces surgical intervention with biochemical modulation of estrogen pathways, eliminating mechanical risks while reducing breast tissue growth.

Positive allosteric modulators target distinct M1 receptor sites to enhance cognitive function while avoiding peripheral cholinergic adverse effects.

Covalent KRAS G12C inhibitors bind active GTP-bound conformations to overcome phospho-ERK rebound resistance in colorectal cancers.

A chimeric peptide links a cyclin kinase inhibitor to a transport sequence for targeted cellular delivery.

Altered sugar moiety in glycolipid structure boosts IFN-gamma production while suppressing IL-4, resolving immunostimulatory activity constraints.

PKC activating compounds mitigate ALS progression by inducing synaptogenesis, countering muscular weakness and atrophy.

Developing crystalline polymorph Form I maleate salt achieves selective deoxycytidine kinase inhibition for treating cancer and autoimmune diseases.

Specific crystalline forms of mGlu5 modulators treat tuberous sclerosis complex while minimizing adverse side effects from conventional antiepileptics.

Formula I heteroaromatic compounds inhibit PI3K and mTOR pathways to overcome resistance in PIK3CA-mutant cancers.

Covalent chitosan attachment to oxidized nanocrystalline cellulose enables controlled release while resolving solubility and aggregation issues.

Targeting CTGF with antisense oligonucleotides reduces fibrosis while preserving wound healing functions blocked by TGF-beta inhibition.

Replacing menthol with cyclic carboxamide coolants eliminates irritation, volatility, and crystallization while sustaining effective cooling.

Genetically engineered bacteria use oxygen-dependent promoters to produce therapeutic molecules in the gut.

Modifying amino acid structures inhibits Bcl-2 family proteins, overcoming chemoresistance and restoring apoptosis in cancer treatment.

Automated metering and buffering stabilize pH levels while preventing uncontrolled dissolution of high solubility vitamins.

Pre-fused PROTACs in lipid nanoparticles overcome hook effects and low permeability to boost degradation efficiency.

Porous hydrogel in custom oral appliance releases antimicrobials to reduce periodontal pocket depth without invasive procedures.

A novel crystalline dihydrate of Rivaroxaban overcomes low bioavailability by utilizing a formic acid solvate intermediate for scalable manufacturing.

Cellulose-inorganic composite particles reduce apparent specific volume and scattering while improving tablet hardness and uniformity.

A pre-primed nasal delivery device sprays a pharmaceutical solution containing naloxone hydrochloride.

N-thiolated beta-lactam moieties overcome pathogen resistance mechanisms to treat infections caused by MRSA and other resistant strains.

Potassium and sodium citrate salts modulate extracellular pH to increase cancer cell sensitivity to anti-PD-1 antibody treatments.

Naphthyridine derivatives inhibit cancer pathways with high specificity, reducing side effects while maintaining treatment effectiveness.

Pre-treating moringa above 80°C inactivates enzymes that decompose benzyl glucosinolates during low-temperature solvent extraction, preventing substance loss.

Heterocycle-substituted tetracyclic compounds inhibit HCV NS5A to reduce viral load and prevent liver disease progression.

Humidified atmosphere removes organic solvent from biopolymer structures through vapor pressure exchange.